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Abstract: BACKGROUND Sexual dimorphism in cardiac sympathetic outflow has recently gained at-
tention in the context of Takotsubo cardiomyopathy. Previous studies suggest that there are sex- and
age-dependent differences in peripheral autonomic control, however, data on cardiac-specific sympathetic
activation in aged women and men are lacking. METHODS AND RESULTS Regional quantitative anal-
ysis of cardiac fluorine-18 (18F)- Dihydroxyphenylalanine (DOPA) uptake was retrospectively performed
in 133 patients (69 females, mean age 52.4±17.7 years) referred for assessment of neuroendocrine tumours
(NET) by Positron-Emission-Tomography. Cardiac 18F-DOPA uptake was significantly higher in women
as compared to men (1.33±0.21 vs. 1.18±0.24, p<0.001). This sex-difference was most pronounced in
the apical region of the left ventricle (LV, 1.30±0.24 in women vs. 1.13±0.25 in men, p<0.001) and in
individuals >55 years of age (1.39±0.25 in women vs. 1.09±0.24 in men, p<0.001). Women showed a
prominent increase in myocardial 18F-DOPA uptake with age with the strongest increase seen in the LV
apical region (r = 0.34, p = 0.004). Accordingly, sex and age were selected as significant predictors of
LV apical 18F-DOPA uptake in a stepwise linear regression model. No age-dependent changes of cardiac
18F-DOPA uptake were observed in men or in the right ventricular region. CONCLUSION Our study
suggests that aging is related to sex-specific changes in regional cardiac sympathetic activity. Future
studies will have to assess whether the increase in LV apical 18F-DOPA uptake with age in women is
of pathogenic relevance for the higher susceptibility of postmenopausal women to conditions associated
with increased sympathetic activity.
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Sexual dimorphism in cardiac sympathetic outflow has recently gained attention in the con-
text of Takotsubo cardiomyopathy. Previous studies suggest that there are sex- and age-
dependent differences in peripheral autonomic control, however, data on cardiac-specific
sympathetic activation in aged women and men are lacking.
Methods and results
Regional quantitative analysis of cardiac fluorine-18 (18F)- Dihydroxyphenylalanine (DOPA)
uptake was retrospectively performed in 133 patients (69 females, mean age 52.4±17.7
years) referred for assessment of neuroendocrine tumours (NET) by Positron-Emission-
Tomography. Cardiac 18F-DOPA uptake was significantly higher in women as compared to
men (1.33±0.21 vs. 1.18±0.24, p<0.001). This sex-difference was most pronounced in the
apical region of the left ventricle (LV, 1.30±0.24 in women vs. 1.13±0.25 in men, p<0.001)
and in individuals >55 years of age (1.39±0.25 in women vs. 1.09±0.24 in men, p<0.001).
Women showed a prominent increase in myocardial 18F-DOPA uptake with age with the
strongest increase seen in the LV apical region (r = 0.34, p = 0.004). Accordingly, sex and
age were selected as significant predictors of LV apical 18F-DOPA uptake in a stepwise lin-
ear regression model. No age-dependent changes of cardiac 18F-DOPA uptake were
observed in men or in the right ventricular region.
Conclusion
Our study suggests that aging is related to sex-specific changes in regional cardiac sympa-
thetic activity. Future studies will have to assess whether the increase in LV apical 18F-
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DOPA uptake with age in women is of pathogenic relevance for the higher susceptibility of
postmenopausal women to conditions associated with increased sympathetic activity.
Introduction
Cardiovascular disease is the leading cause of death and disease burden in both, women and
men, in the western world. While cardiovascular mortality rates have rapidly declined since the
late 1970s in men, death rates in women have not improved to the same extend. In fact, the dis-
ease is becoming more common in women, in particular in young women, and cardiovascular
deaths in women currently exceed those in men.[1, 2] However, there is currently only limited
data on sex-specific pathogenesis, management, and outcomes of cardiovascular disease.
Sexual dimorphism in cardiac sympathetic outflow has recently gained increasing attention
in the context of Takotsubo cardiomyopathy or cardiac syndrome X.[3–6] The worse out-
comes observed in women with cardiovascular disease as well as their higher susceptibility to
cardiac injury during high-stress situations implies that sex-differences in autonomous ner-
vous control of the cardiovascular system might be pathogenetic.[7, 8] However, there is a lack
of data on sex- and age-specific cardiac sympathetic activity in normal individuals and very lit-
tle information about regional norepinephrine turnover, uptake, and metabolism in the
human myocardium is available in the literature. Indeed, previous quantification of sympa-
thetic activity in humans was mainly obtained by unspecific approaches such as power spectral
analysis of heart rate variability (HRV), measurement of muscle sympathetic nervous activity
(MSNA) or quantification of circulating catecholamine levels and have produced widely vary-
ing results.[9, 10] Notably, while MSNA seems to be a good indicator of cardiac or renal sym-
pathetic activity and vasoconstrictor tone in men, studies investigating this association in
women are sparse and have failed to detect a significant correlation between MSNA and car-
diac output or vasoconstrictor tone.[11]
Measurement of regional cardiac sympathetic activity by sympathetic neurotransmitter
radionuclide analogues (e.g. 123I-Metaiodobenzylguanidine [MIBG]) has been shown to add
incremental prognostic value in predicting disease progression in heart failure patients beyond
that provided by traditional markers.[12] Hence, regional dysfunction of the sympathetic ner-
vous system might add important prognostic information about cardiac vulnerability of
women and men and may help to direct preventive strategies and therapy. Besides 123I-MIBG
for scintigraphy, an 18F labelled Positron-Emission-Tomography (PET) tracer was developed
using the catecholamine precursor fluorine-18 (18F)-Dihydroxyphenylalanine (18F-DOPA) to
image active paragangliomas, tumours derived from the autonomous nervous system.[13]
Given the different susceptibility of postmenopausal women and older men to cardiac con-
ditions associated with sympathetic dysregulation, we hypothesized that sex- and age-depen-
dant differences exist with regard to cardiac autonomic control. As the superior spatial
resolution of PET allows to assess even small differences in tracer uptake, the primary aim of
our study was the quantification of regional cardiac 18F-DOPA uptake in men and women free
of cardiovascular disease at different ages.
Methods
Study population
Cardiac uptake of 18F-DOPA was retrospectively assessed in 133 individual patients (69
females, mean age 52.4±17.7 years, range 1–84 years) who underwent functional imaging with
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18F-DOPA PET-CT for evaluation of a known or suspected NET at our institution between
February 2007 and March 2016. Repeated 18F-DOPA exams were excluded from our study.
Information on medical history and cardiovascular risk factors (hypertension, hyperlipidemia,
diabetes, smoking, family history of premature CAD) were obtained from electronic patient
records. Subjects with structural heart disease including heart failure and valvular heart dis-
ease, known obstructive coronary artery disease, previous myocardial infarction, previous cor-
onary artery bypass grafting or percutaneous coronary intervention, hypertension or diabetes
mellitus were excluded from our analysis. The study conforms to the principles outlined in the
1964 Declaration of Helsinki and was approved by the local cantonal ethics committee in
Zurich, Switzerland (BASEC No. 2017–01112). The need to obtain informed consent was
waived by the ethics committee due to the retrospective nature of the study.
Image acquisition and reconstruction
DOPA is a neutral amino acid that resembles natural L-DOPA (dopamine precursor). It enters
the catecholamine metabolic pathway of endogenous L-DOPA in the brain and peripheral tis-
sues and can be labeled with 18F (half-life 110 min) for PET imaging. Incerased uptake of
18F-DOPA is seen in tissues with high activities of L-DOPA decarboxylase. 18F-DOPA-PET was
used at our institution after its formal approval for use in Europe (November 2006). Patients
were asked to fast for at least 4–6 h before 18F-DOPA injection. 18F-DOPA-PET was performed
45 min after injection 18F-DOPA (mean 202.8±36.7 MBq, range 25–263 MBq) into a peripheral
vein.[14] Images were acquired in 3D mode on different scanners (Discovery VCT or Discovery
RX (GE-Healthcare, Milwaukee, WI, USA). The imaging protocol consisted of a scout view fol-
lowed by low-dose CT acquisition for attenuation correction and subsequent PET acquisition.
PET emission scans were acquired from the base of the skull to mid-thigh during 20 min (5–7
bed positions of 2–3 min each). Iterative reconstruction and CT-based attenuation correction
were used. PET and CT images were fused using a dedicated software package (AW 5.0
GE-Healthcare). PET scans were acquired without premedication with carbidopa.
Data analysis
Reconstructed data were transferred to an external workstation (Advantage AW 4.4, GE Health-
care) for analysis. On reformatted horizontal long-axis slices, the left ventricle (LV) and right
ventricle (RV) were subdivided into a total of six segments (LV basal and midventricular lateral
wall, LV basal and midventricular septum, LV septal and lateral apical segments, and RV basal
and midventricular lateral wall). Cardiac segments in our study were defined based on the rec-
ommendations of the American Heart Association Writing Group on Myocardial Segmentation
and Registration for Cardiac Imaging.[15] A semiquantitative analysis of regional 18F-DOPA
uptake was performed by placing a circular volume of interest (VOI) of 2.3cm3, automatically
generated by the computer, into these four segments. The size of the VOI was standardized for
all images by using a semi-automatic volume analysis tool (GE Healthcare, Milwaukee, USA). A
semiquantitative uptake analysis using the upper limit of the standardized uptake value (SUVmax)
and the averaged standardized uptake value (SUVmean) was used to quantify
18F-DOPA uptake
in these regions. SUVmax and SUVmean were normalized to blood pool
18F-DOPA activity mea-
sured in the aortic arch of each patient (= SUVmax-N and SUVmean-N).
Statistical analysis
Data are presented as mean ± standard deviation (SD) for continuous variables and frequency
and percentage for categorical variables. Data were stratified for sex and age. The age of 55
years was used as a cut-off value to differentiate between younger and older individuals. This
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cut-off value was chosen given that most women undergo menopause between 45 and 55 years
and that, at the age of 55 years, 95% of women are postmenopausal.[16] Prior to analyses, basic
assumptions were checked. Student’s t-test, Mann-Whitney test, analysis of variance
(ANOVA) or Kruskal-Wallis test were used for group comparisons of continuous variables.
For comparison of different age- and sex-groups, p-values were adjusted by the Bonferroni
correction for multiple tests. For categorical variables, chi-square tests or Fisher’s exact test
were used, as appropriate. Multivariate linear regression analysis was applied to assess the asso-
ciation of age and sex with regional cardiac sympathetic activity. All tests were two-sided, and
p values below 0.05 were considered significant. Statistical analyses were performed with IBM
SPSS statistics v24.0 and GraphPad Prism (v4.0, GraphPad Software, San Diego, CA).
Results
Patients characteristics
Regional quantitative analysis of cardiac 18F-DOPA uptake was performed in reconstructed
PET/CT images of all 133 patients. All patients were specifically referred for 18F-DOPA PET-
computed tomography (CT) for evaluation of a known or suspected pheochromocytoma
(n = 26), carcinoid (n = 15), thyroid carcinoma (n = 18), or extra-adrenal paraganglioma
(n = 60, Table 1) according to clinical, biochemical or radiological data. In two cases the reason
for 18F-DOPA PET imaging was the presence of a carcinoma of unknown primary origin, two
patients were referred for evaluation of ectopic adrenocorticotropic hormone production and
10 cases had suspicious hepatic, pancreatic and adrenal masses (Table 1). In 67 (50.4%)
patients 18F-DOPA scans were positive for paraganglioma. When data were stratified by sex,
no significant differences with regard to baseline characteristics were observed between men
and women (p = NS, Table 1), except for BMI, which was significantly higher in men
(p<0.001, Table 1). Clinical indications for 18F-DOPA PET referral and patients characteristics
stratified by sex are depicted in Table 1.
Overall cardiac 18F-DOPA uptake in women and men
As previously reported, mild 18F-DOPA uptake is apparent in the myocardium, peripheral
muscles, esophagus, and in some cases in the mammary glands.[14] Overall cardiac 18F-DOPA
uptake was significantly higher in women as compared to men (p<0.001, Table 1) and
increased significantly with age in women (Pearson r = 0.32, p = 0.008) but not in men (Pear-
son r = -0.003, p = 0.97, data not shown). When overall cardiac 18F-DOPA uptake was mea-
sured in both, 18F-DOPA-negative for NET (n = 66) and 18F-DOPA-positive for NET (n = 67)
patients, no differences in myocardial 18F-DOPA uptake were found (p = NS, data not shown).
The latter was true for both, men and women (p = NS, data not shown). Similarly, when
patients were stratified by medical treatment including antiadrenergic therapy, immunosup-
pressive/anti-inflammatory agents, somatostatin analogues, and thyroid hormone receptor
agonists, no significant differences in myocardial 18F-DOPA activity were found in patients
with and without treatment (1.30±0.23 vs 1.25±0.24 SUVmax-N, p = 0.37 for antiadrenergic
therapy; 1.29±0.29 vs 1.25±0.23 SUVmax-N, p = 0.46 for somatostatin analogues; 1.26±0.24 vs
1.27±0.18 SUVmax-N, p = 0.35 for immunosuppressive/anti-inflammatory agents; and 1.26
±0.25 vs 1.24±0.17 SUVmax-N, p = 0.76 for thyroid hormone receptor agonists).
Sex- and age-dependent changes in regional cardiac 18F-DOPA uptake
When patients were stratified by sex and age ( 55 and> 55 years), women >55 years had the
highest cardiac 18F-DOPA uptake (p<0.05, ANOVA, Fig 1A–1C). 18F-DOPA uptake in the
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LV apical region increased significantly with age in women (p = 0.025 for women >55 years vs
women55 years, Fig 1A), while sex- and age differences in 18F-DOPA uptake were less pro-
nounced in the left midventricular region (Fig 1B) and absent in the RV (Fig 1C). No age-
dependent changes in cardiac 18F-DOPA uptake were observed in men (Fig 1A–1C). When a
sub-analysis in patients >70 years was performed (n = 17 for women and n = 6 for men), we
observed a further increase in LV apical 18F-DOPA uptake in women >70 years, while no such
tendency was seen in older men or in other LV regions. In detail, apical 18F-DOPA uptake was
1.5±0.3 SUVmax-N in women >70 years, 1.3±0.2 SUVmax-N in women >55 and70 years, and
1.2±0.2 SUVmax-N in women55 years (p = 0.003). Conversely, no changes in LV apical
18F-DOPA uptake were observed in men >70 years as compared to younger age groups (1.1
±0.3 SUVmax-N in men>70 years, 1.1±0.3 SUVmax-N in men >55 and70 years, and 1.2±0.3
SUVmax-N in men55 years (p = 0.5). Hence, a positive and significant correlation between
Table 1. Patient baseline, 18F-DOPA PET acquisition characteristics, regional cardiac 18F-DOPA uptake, and clinical indications for 18F-DOPA PET imaging.
Baseline characteristics Total n = 133 Womenn = 69 Menn = 64 p-value
Age (years), mean±SD 52.4±17.7 52.9±19.2 52.0±16.1 0.8
BMI, mean±SD 22.7±6.8 20.4±5.4 25.2±7.2 <0.001
18F-DOPA positive scan, n(%) 67(50.4) 31(44.9) 36(56.3) 0.2
Injected 18F-DOPA dose (MBq), mean±SD 202.8±36.7 204.4±40.1 201.2±32.9 0.6
Reason for referral, n(%) 0.3
Clinical suspicion of carcinoid 5(3.8) 2(2.9) 3(4.7)
Clinical suspicion of pheochromocytoma 13(9.8) 8(11.6) 5(7.9)
Clinical suspicion of extra-adrenal paraganglioma 13(9.8) 6(8.7) 7(11.1)
Treatment control carcinoid 10(7.5) 7(10.1) 3(4.7)
Treatment control thyroid carcinoma 18(13.5) 9(13.0) 9(14.3)
Treatment control pheochromocytoma 13(9.8) 5(7.2) 8(12.7)
Treatment control extra-adrenal paraganglioma 47(35.3) 26(37.7) 21(33.3)
Carcinoma of unknown primary origin 2(1.5) 1(1.4) 1(1.5)
Ectopic ACTH production 2(1.5) 0(0) 2(3.2)
Suspicious mass 10(7.5) 6(8.7) 4(6.3)
Medical treatment
Antiadrenergic compounds 26(19.5) 17(24.6) 9(14.1) 0.12
Immunosuppressive/antiinflammatory agents 13(9.8) 7(10.1) 6(9.4) 0.88
Somatostatin analogues 16(12) 8(11.6) 8(12.5) 0.87
Thyroid hormone receptor agonists 18(13.5) 10(14.5) 8(12.5) 0.74
Total myocardial 18F-DOPA uptake (SUVmax-N), mean±SD 1.26±0.24 1.33±0.21 1.18±0.24 <0.001
Total myocardial 18F-DOPA uptake (SUVmean-N), mean±SD 0.86±0.17 0.94±0.15 0.78±0.14 <0.001
Total LV 18F-DOPA uptake (SUVmax-N), mean±SD 1.31±0.26 1.39±0.24 1.23±0.26 <0.001
Total LV 18F-DOPA uptake (SUVmean-N), mean±SD 0.90±0.18 0.98±0.17 0.80±0.15 <0.001
LV-mid-ventricular 18F-DOPA uptake (SUVmax-N), mean±SD 1.32±0.25 1.39±0.24 1.25±0.25 <0.001
LV-mid-ventricular 18F-DOPA uptake (SUVmean-N), mean±SD 0.91±0.17 0.99±0.15 0.83±0.14 0.001
RV 18F-DOPA uptake (SUVmax-N), mean±SD 1.09±0.21 1.14±0.20 1.02±0.20 0.001
RV 18F-DOPA uptake (SUVmean-N), mean±SD 0.77±0.16 0.82±0.12 0.71±0.17 <0.001
LV-apical 18F-DOPA uptake (SUVmax-N), mean±SD 1.28±0.28 1.30±0.24 1.13±0.25 <0.001
LV-apical 18F-DOPA uptake (SUVmean-N), mean±SD 0.88±0.19 0.94±0.18 0.75±0.16 <0.001
NET, neuroendocrine tumor; ACTH, adrenocorticotropic hormone; SUVmax-N, upper limit of the standardized uptake value normalized to blood pool; SUVmean-N,
averaged standardized uptake value normalized to blood pool; RV right ventricular; LV, left ventricular. Values are indicated as mean±standard deviation (SD) or n(%).
P-values are indicated for women vs men.
https://doi.org/10.1371/journal.pone.0202302.t001
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age and LV apical 18F-DOPA uptake was seen in women (Fig 2A), while age and LV apical
18F-DOPA uptake were not associated in men (Fig 2B). In contrast, left mid-ventricular
18F-DOPA uptake was not associated with age in either sex (r = 0.2, p = 0.083 in women and
r = 0.03, p = 0.8 in men, data not shown). Similar, no age-dependent changes of cardiac
18F-DOPA uptake were observed in the RV (p = NS, data not shown). Fig 3 shows representa-
tive examples of reconstructed cardiac long axis 18F-DOPA-PET-CT images of all sex and age
groups.
Predictors of regional cardiac sympathetic activity
When sex and age were tested in a stepwise linear regression analysis with LV apical and mid-
ventricular 18F-DOPA uptake being the dependent variable, and BMI and pathologic findings
as predictor variables, both, sex and age were identified as significant predictors for LV apical
18F-DOPA uptake (Table 2). The probability was best explained by sex, followed by age
(Table 2). When predictors for left mid-ventricular 18F-DOPA uptake were tested, sex
remained a significant predictor for left mid-ventricular 18F-DOPA uptake, while age was not
selected by this model (Table 3).
Discussion
In this retrospective single centre study, we performed a sex- and age-specific analysis of
regional cardiac sympathetic activity in patients undergoing 18F-DOPA PET-CT for evaluation
of NET. Significantly higher cardiac 18F-DOPA uptake was observed in women as compared
to men. This sex-difference in 18F-DOPA uptake was most pronounced in the apical region of
the LV. With advancing age, 18F-DOPA uptake significantly increased in women, in particular
in the LV apex, while no age-dependent changes of 18F-DOPA uptake were observed in men.
While physiological uptake of 18F-DOPA in extraneuronal tissue including liver, myocar-
dium and peripheral muscles has been described previously [14, 17], our study is the first to
report sex-and age-specific differences in regional myocardial 18F-DOPA uptake in patients
without obvious cardiovascular disease. Given its role as precursor of the neurotransmitters
dopamine, epinephrine, and norepinephrine, enhanced 18F-DOPA uptake mirrors an
increased activity of L-DOPA decarboxylase.[17] The latter is associated with an increased syn-
thesis and turnover of norepinephrine in the adrenergic nerve terminals, thereby signifying an
increase in sympathetic outflow. Accordingly, enhanced cardiac L-DOPA decarboxylase activ-
ities have been associated with increased conversion of [3H]tyrosine to [3H]catecholamine as
well as with a faster metabolic rate of norepinephrine in diabetic rats.[18] Therefore, our
observations suggest a sympathetic dominance in the LV apical region which is progressively
prominent with aging in women but not in men. While our observations are consistent with
earlier studies reporting an increase in systemic sympathetic drive assessed by MSNA or nor-
epinephrine spillover in older subjects, previous MIBG studies have failed to report consistent
data on age- and sex-specific cardiac sympathetic activity.[9, 19, 20] In fact, while Sakata et al.
observed a gradual decrease of 123I-MIBG uptake alongside an increase in 123I-MIBG washout
rate with age in both sexes, Tsuchimochi et al. did not observe any differences in MIBG uptake
based on age or sex.[21, 22] Heterogenous cohorts, small sample sizes as well as differences in
acquisition protocols might have accounted for these discrepancies. In addition, according to
our data, age-dependent changes in LV innervation seem not to be uniform and previous data
Fig 1. Comparative analysis of myocardial 18F-DOPA uptake stratified by age (<55 years and>55 years) and sex.
18F-DOPA uptake was measured in the apical (A), left mid-ventricular (B), and right ventricular (C) region of the
heart. Data are presented as dot plots. Mean values and p-values (overall and post-hoc tests) are indicated.
https://doi.org/10.1371/journal.pone.0202302.g001
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might be inconsistent due to the assumption that the sympathetic nervous system in the
human LV would change homogeneously with age.
While our study clearly demonstrates physiologic changes in regional cardiac sympathetic
activity with age, the mechanisms underlying this age-dependent remodeling of cardiac
Fig 2. Age-dependent increase in 18F-DOPA uptake in women. A. Correlation between age and left ventricular
apical 18F-DOPA uptake (SUVmax-N) in women. Pearson correlation coefficients and p-values are indicated. B.
Correlation between age and left ventricular apical 18F-DOPA uptake (SUVmax-N) in men. Pearson correlation
coefficients and p-values are indicated. Pearson correlation coefficients and p-values are indicated.
https://doi.org/10.1371/journal.pone.0202302.g002
Fig 3. Example of Positron-Emission-Tomography image reconstruction using the pmod cardiac PET modelling tool (pmod version 3.8, PMOD technologies LLC,
Zurich, Switzerland) and quantification of 18F-DOPA uptake in the left ventricular wall. A semiquantitative uptake analysis using the upper limit of the standardized
uptake value (SUVmax-N) and the mean SUV (SUVmean-N) at the sites of physiologic uptake was performed using a planar circular region of interest of 1 cm diameter,
automatically generated by the computer. Left ventricular segments in the horizontal long axis were defined as follows: a = basal septal, b = midventricular septal, c =
apical septal, d = apical lateral, e = midventricular lateral, f = basal lateral. A. Cardiac long axis image of a 41 year old male patient. B. Cardiac long axis image of a 66 year
old male patient. C. Cardiac long axis image of a 39 year old female patient. D. Cardiac long axis image of a 72 year old female patient. Similar thresholds were applied for
all images.
https://doi.org/10.1371/journal.pone.0202302.g003
Cardiac sympathetic activity in women
PLOS ONE | https://doi.org/10.1371/journal.pone.0202302 August 14, 2018 9 / 14
sympathetic outflow remain unclear. Among the postulated mechanisms, age-dependent
changes in hormone levels are notable as well as attenuation of parasympathetic activity in
postmenopausal women.[23] Indeed, several studies have reported an inhibiting effect of hor-
mone replacement therapy on sympathetic activity in postmenopausal women, while lower
testosterone levels have been associated with increased sympathetic excitability in older men
with cardiac hypertrophy.[24–26] In addition, an aging-related decline in norepinephrine
transporter/uptake-1 activity has been suggested to enhance the delivery of catecholamines to
postsynaptic sites.[27] Finally, the observed increase of apical 18F-DOPA uptake in women
>55 years of age could be due to a denser sympathetic innervation as a result of an age-depen-
dent remodeling of the female heart. Indeed, a stronger effect of age on LV size and function
has been observed in women as compared to men as recent observational studies have
reported a higher percentage of small hearts alongside a higher LV ejection fraction in aged
females as compared to younger women and age-matched men.[28]
Although cardiac sympathetic function is adversely altered in many disease states, a causal
relationship between the observed increase in sympathetic activity in postmenopausal females
and their enhanced cardiac vulnerability remains to be established. However, it is known that
during an acute coronary syndrome (ACS), women developed a relative greater magnitude of
sympathetic activation than men which lasts until its resolution at nine months.[29] The latter is
consistent with reports of a worse prognosis in women observed during this time period.[30] In
addition, an enhanced vascular transduction of sympathetic activity into hemodynamic parame-
ters due to a decrease in β-adrenergic vasodilatation has been postulated in older women. [31–
33] Thus, unopposed α-adrenergic vasoconstriction along with enhanced sympathetic activity
might predispose aged females to cardiac susceptibility in high-stress situations. Indeed, cardiac
diseases associated with an augmented neural response to mental stress, such as Takotsubo car-
diomyopathy, are highly prevalent in postmenopausal females.[3] Notably, the distribution pat-
tern of myocardial 18F-DOPA uptake in women>55 years of age mirrors the distribution of LV
dysfunction in Takotsubo cardiomyopathy which is least in the LV base and worst in the cardiac
apex, resulting in apical ballooning. Similarly, an epinephrine-dependent switch from beta(2)-
adrenoceptor-G(i) to G(s) protein signalling with subsequent negative inotropic effect in stress-
induced cardiomyopathy, has been shown to be greatest at the apical myocardium.[34]
In light of the strong association between disease state and sympathetic dysregulation, our
data suggest that the quantification of cardiac sympathetic outflow might add prognostic infor-
mation about cardiac vulnerability in women beyond that provided by traditional risk factors.
Table 2. Stepwise linear regression model for left-ventricular apical 18F DOPA uptake (n = 133).
Independent variables B coefficient (SE) p-value
Male Sex -0.15 (0.045) 0.003
Age 0.004 (0.001) 0.005
Stepwise method was performed among age, sex, body mass index (BMI) and pathologic findings on 18F-DOPA scan.
Only variables staying in the final model are presented. SE, standard error.
https://doi.org/10.1371/journal.pone.0202302.t002
Table 3. Stepwise linear regression model for left mid-ventricular 18F DOPA uptake (n = 133).
Independent variables B coefficient (SE) p-value
Male Sex -0.11 (0.047) 0.01
Stepwise method was performed among age, sex, body mass index (BMI) and pathologic findings on 18F-DOPA scan.
Only variables staying in the final model are presented. SE, standard error.
https://doi.org/10.1371/journal.pone.0202302.t003
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Indeed, there is accumulating evidence that imaging of cardiac sympathetic activity may help
to direct clinical decision making in patients with heart failure, a condition characterized by
dysfunction of the sympathetic nervous system.[12] As increased sympathetic tone can be tar-
geted pharmacologically and non-pharmacologically, early identification of patients at risk
might offer the possibility to select appropriate preventive strategies and tailor therapeutic
approaches. However, despite its FDA approval for heart failure patients, the exact role of car-
diac neuronal imaging is still under debate, and, therefore sympathetic imaging modalities
such as 123I-Metaiodobenzylguanidine (mIBG) scintigraphy or 11C-mHED PET are still mostly
applied as a research method.[12, 35–37] Nevertheless, the limited prognostic value of current
diagnostic strategies in women,[38–41] their overall higher cardiovascular mortality, and the
increasing prevalence of cardiovascular disease due to the ageing of the population emphasize
the need to better identify and understand the substrate that places postmenopausal women at
risk. Further research is needed to assess whether sex-differences in cardiac sympathetic activ-
ity may account for the higher cardiovascular mortality seen in women and the different out-
comes observed in pre- and post-menopausal women. In addition, larger-scale investigations
are warranted to delineate whether regional cardiac sympathetic activity adds an incremental
prognostic value in predicting cardiovascular risk beyond that provided by traditional func-
tional and neurohormonal markers.
As with any study, certain design limitations are inherent. First, this study is a retrospective
analysis from a single center, which limits its generalizability. Second, no follow-up data were
available from our study cohort, thus, no conclusions can be made regarding an association
between regional cardiac sympathetic activity and the risk of future adverse cardiovascular
events. Third, no standardized dose and timing of 18F-DOPA PET currently exists and the
18F-DOPA activity administered varies largely in the literature.[17] However, the 45 min time
interval between injection and acquisition as well as the administered dose of 202.8±36.7 MBq
in our study lies within in the range of doses and timing reported in recent studies and has
been recommended by the 2012 European Association of Nuclear Medicine (EANM) guide-
lines.[42] Fourth, unspecific uptake of radiolabeled amino acids in inflamed tissue, scar tissue,
irradiated or ischemic areas has been reported and cannot be excluded in the present study.
However, given that our study subjects did not have abnormalities suspicious of heart disease,
it is unlikely that ischemic or inflammatory cardiac processes account for our findings. Finally,
although no difference in cardiac 18F-DOPA uptake between 18F-DOPA positive and negative
scans were observed, an effect of NET on cardiac DOPA decarboxylase activity cannot be
ruled out in our study. Similarly, as myocardial perfusion imaging has not been performed in
our study and despite the normalization of myocardial uptake to blood pool 18F-DOPA activ-
ity, an effect of myocardial blood flow on tracer kinetics cannot be completely excluded.
Taken together, our study suggests that a sympathetic dominance in the LV apex becomes
progressively prominent with aging in women but not in men. Our data point out that under-
standing the multifactorial nature of cardiac autonomic modulation may provide diagnostic
insights for a sex-specific cardiovascular disease management. Such a personalized approach
will become ever more important in the upcoming years, given the ageing of the population
and the increasing burden of environmental stress and cardiovascular disease. Future studies
will have to evaluate whether there is a clinical role for cardiac neuronal imaging in phenotyp-
ing patients at risk for future cardiac events.
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